Featured Articles

AstraZeneca’s inhaled medicine Trixeo Aerosphere has become the first pressurised metered-dose inhaler (pMDI) to be approved in the UK using a next-generation propellant with near-zero…
Read More...

Novo Nordisk presented data from the phase 3 REAL8 basket study, which showed that once-weekly Sogroya (somapacitan) was non-inferior to the once-daily growth hormone Norditropin…
Read More...

Amneal Pharmaceuticals, Inc. and Apiject Systems, Corp. announced a strategic collaboration to expand domestic production of Apiject’s BFS-based injectable platform at Amneal’s…
Read More...

Novo Nordisk has announced that the FDA has accepted the New Drug Application (NDA) for a once-daily 25 mg oral formulation of Wegovy (semaglutide) for chronic weight management in…
Read More...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Alvotech announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI™…
Read More...

QIAGEN announced the expansion of its cell and gene therapy (CGT) portfolio with enhanced digital PCR (dPCR) solutions tailored for lentivirus-based applications. These solutions are…
Read More...

Boehringer Ingelheim, the University of Oxford, and Cumulus Neuroscience are joining forces to provide insights into the day-to-day experiences of people living with psychiatric…
Read More...

Merck, known as MSD outside the U.S. and Canada, has announced the start of construction on a $1 billion, 470,000-square-foot Biologics Center of Excellence in Wilmington, Delaware.…
Read More...

Regeneron Pharmaceuticals, Inc. announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies (“Fujifilm”) to…
Read More...

Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into a research collaboration and…
Read More...

Roche announced that it will invest USD 50 billion into the United States of America in the next five years. These investments further strengthen Roche’s already significant US…
Read More...

uniQure N.V. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to AMT-130 for the treatment of Huntington’s disease, a rare,…
Read More...

The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU)…
Read More...

Boehringer Ingelheim and Cue Biopharma, Inc. announced a strategic research collaboration and license agreement to develop and commercialize Cue Biopharma’s CUE-501 product candidate, a…
Read More...

Roche announced that the European Commission has approved Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of adult patients with relapsed…
Read More...

Bristol Myers Squibb announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class…
Read More...

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA)…
Read More...

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD).…
Read More...

The US Food and Drug Administration (FDA) has granted orphan drug designation to rilzabrutinib, an investigational, novel, advanced, oral, reversible Bruton’s tyrosine kinase (BTK)…
Read More...

Amneal Pharmaceuticals, Inc. and Shilpa Medicare Limited announced the U.S. launch of BORUZU, a new presentation of bortezomib for ready-to-use subcutaneous administration or…
Read More...